The technology's advantages are well known, but less clear is whether they will be sufficient to compete with entrenched approaches like immunoassays.
The company has developed a series of cytokine immunoassays for its Ciraplex platform that it said can achieve sensitivity in the femtogram per ml range.
Medicare contractors Palmetto GBA, Noridian Healthcare Solutions, and CGS Administrators have all proposed reimbursement coverage for the ProMark test.
Total revenues were down to $505,000 from $951,000 in the year-ago quarter as OVA1 test sales dropped to 2,265 from 3,783 in the first quarter of 2015.
The company plans to make the platform available to collaborators conducting research on exosomal biomarkers with the aim of development new diagnostics.
In PLOS this week: canine GWAS of skeletal syndromes, Chagas disease outcomes and genetic ancestry, and more.
A team describes its idea for a clinical trial data-sharing database, called Vivli, ScienceInsider reports.
One case illustrates how DNA evidence can incriminate an innocent person, Scientific American says.
A lack of stability in research funding drives researchers away from academia, researchers write at eLife.